Abstract Objective: To examine trends in prescribing of angiotensin II receptor blockers (ARBs) as initial and second-line treatment of hypertension. Methods: We performed a cohort study in the Integrated Primary Care Information database, a general practice research database in The Netherlands. We included hypertensive patients who were newly treated with antihypertensive drugs between 1996 and 1999. Initial treatment was defined as the first prescribed antihypertensive drug after diagnosis of hypertension. As secondline treatment, we considered prescriptions of a second antihypertensive drug class, either as switch or addition. We used logistic regression and Cox proportional hazard analysis to estimate time trends in use of ARBs as initial or second-line treatment. Results: In total, 8% of the 3,102 newly treated hypertensive patients received ARBs as initial treatment. Initial ARB use increased significantly from 4% to 10% during the period 1996-1999, whereas calcium channel blocker and angiotensin-converting enzyme inhibitor (ACE-I) use decreased. ARBs were used as second-line treatment in less than 4% of 2,544 patients who were initially treated with an antihypertensive drug other than an ARB: 2% switched to an ARB (mostly from ACE-Is) and 1% received ARBs as add-on treatment. Diuretics and beta-blockers were used five to ten times more often as add-on treatment than ARBs. Conclusion: ARBs achieved a position in the treatment of hypertension as initial rather than second-line therapy.
Introduction
Angiotensin II receptor blockers (ARBs) form the newest class of antihypertensive agents, which have been available in The Netherlands since 1995. Their efficacy in lowering blood pressure is comparable to other antihypertensive drug classes, but they are suggested to be better tolerated and therefore are an attractive option for the treatment of hypertension [1] [2] [3] . During the first years after their introduction, however, there was no evidence from large clinical trials of their benefits on cardiovascular morbidity and mortality. In 2001, benefits of ARBs were demonstrated in patients with heart failure, and in hypertensive patients with coexisting diabetes, proteinuria or microalbuminuria [4] [5] [6] [7] . The first clinical trial looking at hard endpoints in a large group of patients with essential hypertension was published in 2002 [8] . Recently, doubts were raised regarding long-term safety of ARBs [9] . Therefore, in most national and international hypertension guidelines, ARBs have no place as initial treatment in hypertension and are only recommended as second-line treatment in patients who require angiotensin-converting enzyme inhibitors (ACE-Is) but do not tolerate them [10, 11] . Patients for whom ACE-Is are preferred are those with coexisting heart failure, diabetes, proteinuria or renal insufficiency.
Several studies have shown the discrepancy between prescribing patterns in hypertension and guideline recommendations [12] [13] [14] . These studies did not include ARBs as (separate) drug class. Also, studies describing initial and second-line use of antihypertensive drugs did not provide specific information on ARB use [15] [16] [17] . Recently, it was shown that prescribing of ARBs increased rapidly in the late 1990s, but it is unclear to what extent this involved initial or second-line therapy for hypertension [18, 19] .
The objective of this study was to examine trends in prescribing of ARBs as initial and second-line treatment of hypertension in the years after their introduction on the market.
Methods

Setting
We used data from the Integrated Primary Care Information (IPCI) database from the Erasmus Medical Center in The Netherlands. This is a longitudinal general practice research database containing the complete electronic medical records from more than 100 participating Dutch general practitioners (GPs). The electronic records contain coded and anonymous data on patient demographics, symptoms (in free text), diagnoses (using the International Classification for Primary Care [20] and free text), laboratory findings, referrals and drug prescriptions. To maximise completeness of the data, GPs who contribute to the IPCI database are not permitted to use paper-based records. The database complies with European Union guidelines on the use of medical data for medical research and has been proven valid for pharmaco-epidemiological research in several studies that evaluated the quality of the available data [21] .
Study period and population
In this cohort study, we included patients with a diagnosis of hypertension who were newly treated with antihypertensive drugs between 1 January 1996 and 31 December 1999, following the introduction of the first ARB on the Dutch market in March 1995. Hypertension was defined as a coded diagnosis of hypertension (ICPC: K85, K86, K87) [20] or a free text listing of hypertension in the patient record. This latter group was manually evaluated to include only those patients for whom hypertension was mentioned as their diagnosis. Patients were excluded if they already had received antihypertensive drugs in the 6 months preceding their diagnosis of hypertension.
Definitions of initial and second-line treatments As initial treatment, the first prescription of antihypertensive drug therapy within the 6 months after diagnosis of hypertension was classified as a diuretic, beta-blocker, calcium channel blocker, ACE-I, ARB or combination of these (fixed or co-administered). The course of antihypertensive therapy was followed for 1 year to determine which second-line treatment was started after initial monotherapy. Second-line treatment was defined as the second step in the treatment strategy, which can consist of a switch to or an addition of a different antihypertensive drug class. We chose a follow-up period of 1 year, because most changes in antihypertensive treatment occur during the first year of treatment [22] . To characterize the course of treatment, four mutually exclusive categories were distinguished depending on the timing and type of subsequent antihypertensive drug prescriptions: continuation, discontinuation, switch or add-on treatment. Continuation was defined as receiving a repeat prescription for the initial drug class at least every 6 months and no prescription for any other antihypertensive drug class during follow-up. Discontinuation was defined as having no prescription for any antihypertensive drug class during the 6 months following the date of the last prescription of the initial drug class. A switch in treatment was considered if an alternative antihypertensive drug class was prescribed within 6 months after a discontinuation of the initial drug class. Add-on treatment was defined as receiving a prescription for a different antihypertensive drug class in addition to a prescription of the initial drug class, simultaneously or in the following 3 months.
Data analyses
A descriptive analysis characterized the study population and defined subgroups according to calendar year and type of initial antihypertensive drug treatment. Differences in patient characteristics between year cohorts were tested using chi-square tests. To assess whether the initial treatment changed over the study years, odds ratios for calendar year were estimated using logistic regression analysis adjusting for age and sex. Separate models were run for each antihypertensive drug class. To compare second-line treatment in different year cohorts, Cox proportional hazard analysis was used to calculate age-and sex-adjusted hazard ratios for each drug class. This analysis takes possible differences in follow-up time into account. Subgroup analyses were conducted excluding patients with prevalent comorbid conditions that may affect ARB use, i.e. heart failure, diabetes, proteinuria and/or renal insufficiency.
Results
We identified 3,102 hypertensive patients who received an initial antihypertensive treatment. Patients had a mean age of 58 years and 58% were female (Table 1) . Patients who started antihypertensive treatment later during the study period were somewhat younger (v 2 -test P=0.153). The proportion of male patients increased significantly from 37% in 1996 to 45% in 1999 (v 2 -test P=0.017). Hypertensive patients with heart failure, diabetes, proteinuria and/or renal insufficiency represented 14% of the study population.
Initial antihypertensive treatment
Initial use of each antihypertensive drug class differed between various patient subgroups, e.g. by sex and age ( Table 1) . Examination of time trends of initial antihypertensive treatment demonstrated marked changes between 1996 and 1999: the percentage of ARBs as initial treatment increased from 4% to 10%, diuretics increased from 18% to 25%, whereas use of calcium channel blockers fell from 12% to 6% and ACE-Is from 23% to 18%. These time trends remained significant after adjustment for sex and age (Table 2 ). Initial use of beta-blockers remained stable over the years (31%). Also, initial use of combination therapy remained stable, but there was a significant increase of combination therapies consisting of ARBs (from 0.2% to 2%).
Restriction of the analyses to hypertensive patients without heart failure, diabetes, proteinuria and/or renal insufficiency showed similar time trends in initial use of ARBs (data not shown).
During the first year of follow-up, 31% of patients continued their initial treatment, 30% discontinued treatment, 12% switched therapy, 19% received add-on therapy and 8% did not have 1 year of follow-up (Table 3) . Initial users of ARBs discontinued treatment less frequently (22%) than those who started on diuretics (39%), beta-blockers (29%), calcium channel blockers (30%) or ACE-Is (26%). Initial users of ARBs had a slightly lower proportion of switches, but received somewhat more add-on therapies than initial users of other antihypertensive drug classes (Table 3) .
Second-line antihypertensive treatment
Of the 2,544 patients who were initially treated with an antihypertensive drug other than an ARB, 59 patients switched to ARBs (2.3%). This rate is comparable to the percentages of switches to diuretics and calcium channel blockers (Table 4 ). Switches to beta-blockers (5.4% of patients starting on another drug) and ACE-Is (4.3%) occurred about twice as often. Of the 59 switches to an ARB, 32 originated from initial ACE-I use (54%). Hypertensive patients without heart failure, diabetes, proteinuria and/or renal insufficiency switched just as much to ARBs (on average 2.4%) as patients with these comorbidities. Percentage of switches to ARBs increased significantly from 1.1% in 1996 to 3.0% in 1997, but decreased again to 1.7% in 1999. The same pattern was observed in the Cox regression analysis when we accounted for variable follow-up time (Table 5) .
Of the 2,544 patients who were initially treated with an antihypertensive drug other than an ARB, 36 patients received ARBs as add-on treatment (1.4%). Hypertensive patients without heart failure, diabetes, proteinuria and/or renal insufficiency received comparable percentages of ARBs as add-on treatment (1.3%). Add-on therapies with other drug classes were far more common than with ARBs, especially the addition of diuretics (11.7% of patients starting on another drug) and betablockers (6.5%). The percentage of add-on treatment with ARBs increased gradually from 0.4% in 1996 to 2.2% in 1999; patients in cohort 1999 received ARBs significantly more often as add-on treatment than those in 1996 (Table 6 ).
Discussion
This study provides an overview of the uptake of ARBs in the treatment of hypertension in The Netherlands. Initial use of ARBs increased substantially in the years following their introduction, mostly at the expense of calcium channel blockers and ACE-Is. The use of ARBs as second-line treatment was much lower. In 1999, more than 10% of the newly treated hypertensive patients received an ARB as initial treatment, whereas less than Table 4 Second-line treatment choice: switches and add-on therapy. DIU diuretic, BB beta-blocker, CCB calcium channel blocker, ACE-I angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker Initial antihypertensive drug treatment (16) 191 (19) 38 (14) 131 (21) 59 (25) 521 (19) with DIU -121 (12) 14 (5) 76 (12) 39 (17) 250 (12) (2) 11 (1) 3 (1) 12 (2) -36 (1) a Switches or add-on therapies to combinations of two different antihypertensive drug classes are counted in both classes (n=27). Therefore, the numbers in each column may add up to more than the total of switches or add-on therapies Table 5 Time trends in second-line treatment of different antihypertensive drug classes due to a treatment switch. Hazard ratios for calendar year were adjusted for sex and age. Separate models were run for each of the five drug classes. CCB calcium channel blocker, ACE-I angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker 4% of all patients who were initially treated with another antihypertensive drug received an ARB as secondline therapy in the following year. Switching to an ARB occurred slightly more often than the addition of an ARB as second-line treatment, but we did observe an increasing rate of add-on treatments with ARBs by the year 1999. Patients who switched to ARBs mostly came from initial treatment with an ACE-I. Beta-blockers and diuretics remained the most common initial and secondline treatment choice in The Netherlands. If guideline recommendations had been followed during our study period, one would have expected ARBs to be prescribed mostly as second-line treatment, especially in patients unable to tolerate ACE-Is [10, 11] . Contrary to these expectations, ARBs were not very popular as second-line treatment, but instead achieved a significant position as initial treatment for hypertension. As we reported elsewhere, this position was not restricted to patients with relevant comorbidities [19] . ARBs were already used as initial treatment in uncomplicated hypertensive patients before trials on cardiovascular endpoints became available. A previous study indicated a similar pattern regarding ACE-Is shortly after their introduction [12] . While the prescribing of ACE-Is seems to have developed into a pattern that is more in accordance with guideline recommendations [19] , this appears not (yet) to be the case for the ARBs.
Studies showing that ARBs are better tolerated and have higher persistence rates than other antihypertensive drug classes probably encouraged prescribing of these newer drugs as the initial treatment [25, 26] . It is likely that promotional activities of the pharmaceutical industry accelerated the dissemination and adoption of these views [27] . Pharmaceutical companies in The Netherlands devoted substantial resources to promote the advantages of ARBs in terms of efficacy and tolerability [28] . For pharmaceutical companies, there was a lot at stake when patents of a number of antihypertensive drugs, mainly ACE-Is, expired. For GPs, however, there were no restrictions to prescribe the newer, more expensive drugs nor incentives to prescribe generic drugs at that time.
Another factor in the uptake of new drugs concerns the influence of specialists. Especially for cardiovascular drugs, a substantial impact has been observed on the GPs' prescribing [29] . In The Netherlands, prescriptions initiated by specialists are often continued by GPs. This obviously affects the prevalent use of ARBs in general practice [19] . In this study, however, we looked at first prescriptions within 6 months after a diagnosis of hypertension. These will mostly be prescriptions initiated by the GPs themselves. Moreover, the rapid increase in the use of ARBs immediately after their introduction on the market also suggests that GPs have started to prescribe these drugs on their own initiative.
The increased initial treatment with ARBs occurred at the expense of calcium channel blockers and ACE-Is. The debate on controversial results regarding the safety of calcium channel blockers around 1996 may have played a role in the decreased prescribing of calcium channel blockers [30] . The increased rate of ARBs as add-on therapy may be a result of an intensified treatment of hypertension. Guidelines recommend the addition of a second drug from a different class when adequate blood pressure levels are not achieved. However, only one in every five patients received an add-on therapy in the first year of treatment. This confirms the findings from previous studies showing that hypertension is undertreated in The Netherlands [23, 24] . Moreover, 30% of all newly treated patients discontinued treatment in the first year, which is similar to results from other studies [15] [16] [17] . This implies that there is still much room for improvement in hypertension treatment. This is the first study that focused on the uptake of ARBs in the treatment of hypertension, and made a distinction between initial and second-line treatment. Other studies which described prescribing patterns of initial and second-line antihypertensive drugs gave no clear information on ARB use [15] [16] [17] . A strength of this study is that we used routinely collected data from a large, longitudinal general practice database comprising information about diagnosis and prescriptions at the patient level. This allowed us to follow dynamics in prescribing patterns in cohorts of individual newly treated hypertensive patients in the years following the introduction of ARBs. A limitation of this study lies in our definitions of initial and second-line treatment. We identified changes in treatment in a period of 6 months, which is a commonly used time window. This covers twice the maximum period of 3 months that may be Table 6 Time trends in second-line treatment of different antihypertensive drug classes due to add-on treatment. CCB calcium channel blocker, ACE-I angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker. Hazard ratios for calendar year were adjusted for sex and age. Separate models were run for each of the five drug classes supplied by one prescription for antihypertensive drugs in The Netherlands. Although this study focused on the uptake of ARBs, it may have implications for understanding the adoption process of other new therapeutic drug classes. It appears that newer, more expensive drug classes are chosen soon after their introduction on the market, not primarily for patients who do not respond satisfactorily to previous treatment, but often in newly treated patients without specific reasons. Since benefits on hard endpoints are often not established and also long-term risks are not known, this may have important consequences on health care.
In conclusion, ARBs have achieved a position in the treatment of hypertension as initial rather than secondline therapy which is not in accordance with the existing guideline recommendations for hypertension.
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